Seoul, South Korea

Mooyoung Seo

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Mitoimmune Therapeutics Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mooyoung Seo. Retrieved from https://idiyas.com/inventor/mooyoung-seo-ulcytztk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mooyoung Seo: Inventor of a Stable Crystalline Form

Introduction

Mooyoung Seo is an inventor based in Seoul, South Korea, associated with Mitoimmune Therapeutics Inc. His patent work concerns a crystalline form of a pharmaceutical compound, with a focus on stability and suitability for storage and formulation.

Latest Patents

Seo is named on 1 patent: “Crystalline Forms of 5-[(1,1-Dioxido-4-Thiomorpholinyl)Methyl]-2-Phenyl-N-(Tetrahydro-2H-Pyran-4-yl)-1H-Indol-7-Amine.” The invention describes Crystalline Form A of the compound and reports physical and chemical advantages over its amorphous and other crystalline forms. According to the patent description, the form resists denaturation during prolonged exposure to harsh conditions, absorbs little water, and remains unchanged under pressure or pulverization. These properties are presented as beneficial for formulation and extended storage.

Career Highlights

Seo’s listed patent reflects work on solid-state forms of pharmaceutical compounds. The invention emphasizes characteristics that may support the compound’s handling, processing, and storage.

Collaborations

Seo is associated with Mitoimmune Therapeutics Inc. His listed coworkers include Soon Ha Kim and Hye Kyung Chang.

Conclusion

Mooyoung Seo’s patent centers on a stable crystalline form designed to offer practical advantages in pharmaceutical formulation and long-term storage.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…